V
Vinod Pullarkat
Researcher at City of Hope National Medical Center
Publications - 280
Citations - 9132
Vinod Pullarkat is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 37, co-authored 219 publications receiving 6536 citations. Previous affiliations of Vinod Pullarkat include University of Southern California & Biogen Idec.
Papers
More filters
Journal ArticleDOI
Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.
Ibrahim Aldoss,Jianying Zhang,Raju Pillai,Geoffrey Shouse,James F. Sanchez,Matthew Mei,Ryotaro Nakamura,Anthony S. Stein,Stephen J. Forman,Guido Marcucci,Vinod Pullarkat +10 more
TL;DR: A retrospective analysis of AML patients treated with the combination of VEN/HMA using an in-house next generation sequencing panel found the combination is welltolerated even in frail patients and is associated with low treatment-related mortality (TRM) (DiNardo et al, 2019).
Journal Article
A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
Vinod Pullarkat,Peter P. Lee,Ronaldo Scotland,Valerie Rubio,Susan Groshen,Conway Gee,Roy Lau,Jolie Snively,Shirley Sian,Susan L. Woulfe,Richard A. Wolfe,Jeffrey S. Weber +11 more
TL;DR: The data suggest that the majority of patients with resected melanoma mount an antigen-specific immune response against a multipeptide vaccine administered with SD-9427.
Journal ArticleDOI
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use
TL;DR: Recommendations are offered based on protocol guidelines, published data from clinical trials as well as from analysis of real world evidence from patients treated with this combination of hypomethylating agents and venetoclax.
Journal ArticleDOI
Diagnosis and Management of Immune Thrombocytopenia in the Era of Thrombopoietin Mimetics
TL;DR: The current data on the efficacy and safety of thrombopoietin receptor agonists is reviewed and other therapies as well as diagnostic work up of ITP are discussed.
Journal ArticleDOI
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
Ibrahim Aldoss,Sanjeet Dadwal,Jianying Zhang,Bernard Tegtmeier,Matthew Mei,Shukaib Arslan,Monzr M. Al Malki,Amandeep Salhotra,Haris Ali,Ahmed Aribi,Karamjeet S. Sandhu,Samer K. Khaled,David S. Snyder,Ryotaro Nakamura,Anthony S. Stein,Stephen J. Forman,Guido Marcucci,Vinod Pullarkat +17 more
TL;DR: The overall risk of IFIs during VEN-HMA therapy is low, but the risk is higher in nonresponders and in those who were treated in the r/r setting; these patients need reevaluation of their antifungal prophylaxis to minimize the risk ofIFIs during therapy.